1. Analyst View 2. Research Methodology 3. Duchenne Muscular Dystrophy (DMD): An Overview 4. Market Dynamics 4.1 Market Drivers 4.1.1 Growing Prevalence of Duchenne Muscular Dystrophy 4.1.2 Rising Acceptance of Duchenne Muscular Dystrophy Drugs in the Market 4.1.3 Increasing Funding Support & Grants 4.1.4 Increasing Awareness 4.1.5 Robust and Opportunistic Pipeline 4.2 Restraints 4.2.1 Pediatric Neuromuscular Disease 4.2.2 Lack of Disease History and Research Participants 4.2.3 Diagnosis and Management of Duchenne Muscular Dystrophy in Developing Countries 4.2.4 High Cost of Care 4.3 Opportunities 4.3.1 PPMO: Next Generation Antisense Platform 4.3.2 Growing Market Opportunity in Emerging Countries 4.3.3 High Unmet Need for an Effective Disease Modifying Therapy 4.3.4 Gene Therapy 4.3.5 Utrophin Modulation 4.3.6 Biomarkers for Duchenne Muscular Dystophy 5. Global Duchenne Muscular Dystrophy Therapeutics Market Outlook 2022 6. Approved Drugs 6.1 Emflaza (deflazacort) 6.2 EXONDYS 51 (eteplirsen) 6.3 Translarna (ataluren) 7. Market Segmentation by Therapeutic Approach 7.1 Mutation Suppression 7.2 Steroid Therapy 7.3 Exon Skipping Therapy 8. Market Segmentation by Geography 8.1 Europe 8.2 North America 8.3 Asia Pacific 9. Clinical Trial Assessment & Pipeline Analysis 9.1 Clinical Trials 9.1.1 By Geography 9.1.2 By Clinical Trial Phase 9.1.3 By Key Players 9.2 Pipeline Analysis 10. Industry Trends and Developments 10.1 Administration of Corticosteroids 10.2 Collaboration amongst Industry Players and Non-Industry Participants 10.3 Exon-Skipping Technology Crowding the DMD Therapeutics Industry 10.4 Carrier Screening for Duchenne Muscular Dystrophy 11. Strategic Alliances 12. Competitive Landscape 13. Key Player Analysis 13.1 Marathon Pharmaceuticals, LLC 13.2 PTC Therapeutics, Inc. 13.3 Sarepta Therapeutics, Inc. 13.4 ITALFARMACO S.p.A. 13.5 Santhera Pharmaceuticals 13.6 Bristol-Myers Squibb 13.7 ReveraGen BioPharma, Inc. 13.8 Catabasis Pharmaceuticals, Inc. 13.9 FibroGen, Inc. 13.10 NS Pharma, Inc. 13.11 Pfizer 13.12 Summit Therapeutics plc 13.13 Taiho Pharmaceutical Co., Ltd. (Division of Otsuka Holdings Co. Ltd.) 14. Future Outlook List of Figures: Figure 5-1: Global - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022 Figure 6-1: Global - Sales of EXONDYS 51 (Million US$), 2016 Figure 6-2: Global - Sales of Translarna (Million US$), 2014-2017 Figure 7-1: Global - Duchenne Muscular Dystrophy Therapeutics Market by Therapeutic Approach (%), 2016 Figure 7-2: Global - Mutation Suppression Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022 Figure 7-3: Global - Steroid Therapy Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022 Figure 7-4: Global - Exon Skipping Therapy Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022 Figure 8-1: Global - Duchenne Muscular Dystrophy Therapeutics Market by Geography (%), 2016 Figure 8-2: Europe - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022 Figure 8-3: North America - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022 Figure 8-4: Asia Pacific - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022 Figure 9-1: Global - Duchenne Muscular Dystrophy Clinical Trials by Countries till April, 2017 Figure 9-2: Global - Duchenne Muscular Dystrophy Clinical Trials by Phase till April, 2017 Figure 9-3: Global - Duchenne Muscular Dystrophy Clinical Trials by Key Players till April, 2017 Figure 10-1: Exon Skipping Clinical Candidates Figure 12-1: Global - Share of Major Players in Duchenne Muscular Dystrophy Therapeutics Market (%), 2016 Figure 13-1: PTC Therapeutics, Inc. - Revenue by Geography (%), 2016 Figure 13-2: Santhera Pharmaceuticals - Revenue by Business Segments (%), 2015 Figure 13-3: Santhera Pharmaceuticals - Revenue by Geography (%), 2015 Figure 13-4: Bristol Myers Squibb - Revenue by Business Segments (%), 2015 Figure 13-5: Bristol Myers Squibb - Revenue by Geography (%), 2015 Figure 13-6: FibroGen, Inc. - Revenue by Geography (%), 2016 Figure 13-7: Pfizer Inc. - Revenue by Business Segments (%), 2016 Figure 13-8: Pfizer Inc. - Revenue by Geography (%), 2016 List of Tables: Table 4-1: Grants for Duchenne Muscular Dystrophy Table 4-2: Per-Patient Annual Costs of DMD, 2012 Table 6-1: Ongoing Trials for Emflaza Table 6-2: Ongoing Trials for EXONDYS 51 Table 6-3: Ongoing Trials for Translarna Table 7-1: Disease-Modifying Therapies for Duchenne Muscular Dystrophy Table 9-1: Global Duchenne Muscular Dystrophy Therapeutics Pipeline Table 13-1: Marathon Pharmaceuticals, LLC – Commercialized Duchenne Muscular Dystrophy Products Table 13-2: PTC Therapeutics, Inc. - Key Financials (Million US$), 2014-2016 Table 13-3: PTC Therapeutics, Inc. – Commercialized Duchenne Muscular Dystrophy Products Table 13-4: PTC Therapeutics, Inc. – Product Pipeline Table 13-5: Sarepta Therapeutics, Inc. - Key Financials (Million US$), 2014-2016 Table 13-6: Sarepta Therapeutics, Inc. – Commercialized Duchenne Muscular Dystrophy Products Table 13-7: Sarepta Therapeutics, Inc. – Product Pipeline Table 13-8: ITALFARMACO S.p.A. – Product Pipeline Table 13-9: Santhera Pharmaceuticals - Key Financials (Million US$), 2013-2015 Table 13-10: Santhera Pharmaceuticals – Product Pipeline Table 13-11: Bristol Myers Squibb - Key Financials (Million US$), 2013-2015 Table 13-12: Bristol Myers Squibb – Product Pipeline Table 13-13: ReveraGen BioPharma, Inc. – Product Pipeline Table 13-14: Catabasis Pharmaceuticals, Inc. - Key Financials (Million US$), 2014-2016 Table 13-15: Catabasis Pharmaceuticals, Inc. – Product Pipeline Table 13-16: FibroGen, Inc. - Key Financials (Million US$), 2014-2016 Table 13-17: FibroGen, Inc. – Product Pipeline Table 13-18: NS Pharma, Inc. – Product Pipeline Table 13-19: Pfizer Inc. - Key Financials (Million US$), 2014-2016 Table 13-20: Pfizer Inc. – Product Pipeline Table 13-21: Summit Therapeutics plc – Product Pipeline Table 13-22: Taiho Pharmaceutical Co., Ltd. - Key Financials (Million US$), 2014-2016 Table 13-23: Taiho Pharmaceutical Co., Ltd. – Product Pipeline